American Diabetes Association 82nd Scientific Sessions (ADA 2022)

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

Roshini Claire Anthony, 20220625120001

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

Semaglutide reduces long-term T2D risk in overweight/obese patients

Elaine Soliven, 20220621000000

Once-weekly injection of semaglutide significantly reduced the 10-year risk of developing type 2 diabetes (T2D) among overweight or obese patients, according to a post hoc analysis of the STEP* 1 and 4 trials presented at ADA 2022.

Dulaglutide: A new horizon for T2D treatment in kids

Roshini Claire Anthony, 20220618130001

A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.

EMPRISE shows CV efficacy, safety of empagliflozin in routine care

Audrey Abella, 20220616100000

The final analysis of the 5-year monitoring EMPRISE* programme presented at ADA 2022 demonstrated the cardiovascular (CV) efficacy of empagliflozin in patients with type 2 diabetes (T2D), with a safety profile that aligns with existing evidence.

‘Digital Twin’ tech reverses type 2 diabetes, fixes metabolic disruptions

Jairia Dela Cruz, 20220614140000

A novel artificial intelligence platform that integrates multidimensional data to deliver precision nutrition and health recommendations not only helps to induce remission in type 2 diabetes but also to normalize a range of glycaemic and extraglycaemic parameters, as shown in a study presented at the 82nd American Diabetes Association (ADA) Scientific Sessions.

Higher dairy intake tied to lower T2D risk

Audrey Abella, 20220614100000

Higher consumption of dairy products is associated with a lower risk of type 2 diabetes (T2D) among US adults, according to a nationally representative study presented at ADA 2022.

CREATE: ‘Open-source’ automated insulin delivery gets good results in T1D

Jairia Dela Cruz, 20220613140000

Automating insulin delivery with an open-source algorithm that is run on a smartphone proves safe and effective in the management of type 1 diabetes (T1D), as shown in the results of Community Derived Automated Insulin Delivery (CREATE) trial.

Weight loss boosts quality of life in type 2 diabetes

Tristan Manalac, 20220613090000

Patients with type 2 diabetes (T2D) who lose more weight appear to have better quality of life (QoL), an effect that is independent of treatments received, according to a study presented at the recent 82nd Scientific Sessions by the American Diabetes Association (ADA 2022).

Patients with IGT show poor response to lifestyle changes

Stephen Padilla, 20220610120000

A study of Thai patients with impaired glucose tolerance (IGT) has found only a slight reduction in weight among its participants, highlighting the need for more intensive efforts with structured lifestyle programs to prevent diabetes.

Exercise before or after breakfast helps keep blood sugar in check

Tristan Manalac, 20220610090000

In obese adults, free-living exercise conducted either before or after breakfast leads to notable improvements in body composition and glycaemic control, according to a study presented at the recent 82nd Scientific Sessions by the American Diabetes Association (ADA 2022).